
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Continuous Glucose Monitoring Devices Market**

According to Intelli, the U.S. Continuous Glucose Monitoring Devices Market size was valued at USD 2,660 Million in 2024 and is projected to reach USD 5,263.16 million by 2032, growing at a CAGR of 9.43% from 2025 to 2032.



In the ever-evolving landscape of healthcare technology, where diabetes is playing crucial role as global threat, continuous Glucose Monitoring (CGM) devices have emerged as a transformative innovation in the management of diabetes. It provides real-time, dynamic insights into glucose levels, empowering individuals with diabetes to make informed decisions about their health. Basically, CGMs use a small sensor placed under the skin to measure glucose levels in the interstitial fluid throughout the day and night. After that, this data is transmitted to a monitor or smartphone, providing timely alerts when glucose levels begin to rise or drop outside the target range. These devices not only enhance glycaemic control but also enhancing quality of life by minimizing the need for frequent fingerstick testing. By tracking trends and patterns, CGMs help to make informed decisions about diet, exercise, and insulin dosage and, also reduces the risk of severe complications like hypoglycemia and hyperglycemia.

**U.S. Continuous Glucose Monitoring Devices Market Definition**

The U.S. Continuous Glucose Monitoring Devices Market comprises of dynamic range of industry that focused on the development, production, and sale of CGM systems, aimed to control diabetes. The Continuous Glucose Monitoring devices market is currently in a medium growth stage, with the pace of expansion accelerating steadily. This upward trajectory is driven by several key factors, including the rising global prevalence of diabetes and the growing adoption of CGM technology due to its well-documented clinical benefits.

**U.S. Continuous Glucose Monitoring Devices Market Overview**

The U.S. Continuous Glucose Monitoring devices market is experiencing robust growth, and is characterized by a growing adoption of advanced technologies, such as integrated systems that communicate with insulin pumps and cloud-based platforms for data sharing. The Continuous Glucose Monitoring market segment is expected to register a higher CAGR during the forecast period, driven by its capability to continuously track patients' blood glucose levels in real time. Innovations in sensor accuracy, device miniaturization, and user comfort are further accelerating uptake among both type 1 and type 2 diabetes patients. Research and development (R&D) activities in the continuous glucose monitoring A close-up of hands holding a tablet and a pen

Description automatically generateddevices market are at a moderate level. These efforts play a crucial role in driving innovation, enabling companies to develop new and improved products that enhance performance, and clinical outcomes. Abbott remains actively engaged in research and development efforts to deliver next-generation CGM devices with advanced features and improved performance. Regulatory authorities like the U.S. FDA have established stringent guidelines to ensure the safety, performance, and efficacy of continuous glucose monitoring devices. These regulations have played a vital role in enhancing patient safety and driving improved health outcomes across the market. Moreover, favorable reimbursement policies and heightened awareness of proactive diabetes management have strengthened market penetration.

**U.S. Continuous Glucose Monitoring Devices Market Segmentation**

U.S. Continuous Glucose Monitoring Devices Market is segmented based on component, technology, application, demographics and End-users.

**U.S. Continuous Glucose Monitoring Devices Market, By Component**

* **Sensors**
* **Transmitters & Receivers**
* **Integrated Insulin Pumps**

The U.S. Continuous Glucose Monitoring devices market, segmented by component, is primarily driven by the growing demand for advanced sensors, transmitters & receivers, and integrated insulin pumps. Sensors are the core component responsible for continuously detecting and measuring glucose levels in the interstitial fluid. Their high replacement frequency, due to limited wear-time, makes them a major revenue contributor in the CGM ecosystem. Technological advancements in sensor design like longer wear durations, enhanced accuracy, reduced calibration needs, and improved comfort have significantly increased user adoption. As innovation in sensor technology continues to evolve, sensors remain at the forefront of market expansion. On the other hand, Transmitters and receivers serve as critical communication links, transmitting glucose data from sensors to display devices or smartphones. It increases patient engagement and remote monitoring capabilities. Meanwhile, integrated insulin pumps represent a significant technological advancement, offering automated insulin delivery based on sensor readings, thus streamlining diabetes management. This integration not only improves glycemic control and reduces the risk of hypoglycemia but also enhances patient A close-up of hands holding a tablet and a pen

Description automatically generatedquality of life. As the demand for all-in-one diabetes management solutions grows, integrated insulin pumps are becoming a key driver of innovation and adoption within the CGM market. Together, these components are reshaping the landscape of diabetes care in the U.S., contributing to better glycaemic control.

**U.S. Continuous Glucose Monitoring Devices Market, By Technology**

* **Real-time CGM**
* **Intermittently Scanned CGM**

The U.S. Continuous Glucose Monitoring Devices Market is segmented by technology into Real-time Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring systems. The market impact of Real-time CGM devices is substantial. Real-time CGM devices offer continuous transmission of glucose data to a receiver or smartphone, delivering immediate alerts for high or low blood sugar levels. This real-time feedback supports proactive and timely diabetes management, making it particularly valuable for individuals with type 1 diabetes who need urgent glycaemic control. In contrast, Intermittently Scanned CGM requires users to scan a sensor to obtain glucose readings, offering a more affordable and discreet option with fewer alerts.

**U.S. Continuous Glucose Monitoring Devices Market, By Application**

* **Type 1 Diabetes**
* **Type 2 Diabetes**

The U.S. Continuous Glucose Monitoring devices market, segmented by application, primarily serves individuals with Type 1 and Type 2 diabetes, each presenting distinct needs and usage patterns. Patients with type 1 diabetes, who depend on intensive insulin therapy and precise glycaemic control, form a key segment of CGM system users, especially real-time CGMs, which provide continuous glucose monitoring and timely alerts. Adoption in this segment is high due to the life-long dependency on insulin and the critical need for frequent glucose monitoring. On the other hand, Type 2 diabetes patients are increasingly adopting CGM devices as part of a broader shift toward proactive disease management.

**U.S. Continuous Glucose Monitoring Devices Market, By Demographics**

* **Adult**
* **Paediatrics**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe U.S. Continuous Glucose Monitoring devices market, segmented by demographics, serves both adult and paediatric populations, each with unique clinical and usability needs. The adult segment holds the largest market share, driven by the high prevalence of type 2 diabetes and increasing awareness of proactive glucose management. The pediatric segment is witnessing consistent growth, especially among children diagnosed with type 1 diabetes. CGM systems provide a less invasive, more child-friendly solution compared to traditional fingerstick testing, significantly reducing the physical and emotional strain on both young patients and their caregivers.

**U.S. Continuous Glucose Monitoring Devices Market, By Connectivity**

* **Bluetooth**
* **4G**

The U.S. Continuous Glucose Monitoring devices market, when segmented by connectivity, includes Bluetooth and 4G-enabled devices, both playing a vital role in enhancing real-time data transmission and remote monitoring. Bluetooth-enabled CGM systems dominate the market, offering seamless connectivity with smartphones, smartwatches, and other compatible devices. Bluetooth connectivity enhances user engagement, simplifies data sharing with healthcare providers, and supports app-based insights that improve self-management. In contrast, 4G-enabled CGM devices are gaining momentum due to their ability to support uninterrupted, cloud-based data sharing over longer distances. It is ideal for continuous remote monitoring, especially in telehealth and hospital settings.

**U.S. Continuous Glucose Monitoring Devices Market, By End User**

* **Hospitals & Clinics**
* **Homecare Settings**
* **Diagnostic Centers**

The U.S. Continuous Glucose Monitoring devices market is segmented by end user into Hospitals & Clinics, Homecare Settings, and Diagnostic Centers, each contributing uniquely to market growth. Hospitals & Clinics represent a critical segment where CGM devices are used for acute and inpatient diabetes management. Homecare Settings form the largest and fastest-growing end-user segment, driven by the rising preference for self-monitoring and remote care. Diagnostic Centers utilize CGM devices primarily for short-term glucose profiling and diagnostic evaluations, often as part of diabetes screening, gestational diabetes monitoring, or evaluating treatment efficacy. Together, these end-A close-up of hands holding a tablet and a pen

Description automatically generateduser segments illustrate the versatility and growing demand for CGM devices across both clinical and non-clinical environments

**Key Players**

The “U.S. Continuous Glucose Monitoring devices market " study report will provide valuable insight emphasizing the U.S. market. The major players in the market Abbott, Medtronic, Dexcom, Inc., Senseonics Holdings, Inc., Insulet Corporation, Roche Diabetes Care, Signos, Inc., A. Menarini Diagnostics, Johnson & Johnson, GlySens Incorporated, Tandem Diabetes Care, Nemaura Medical Inc. among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In August 2024, Abbott and Medtronic formed a global partnership to combine Abbott’s FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic’s automated insulin delivery (AID) systems and smart insulin pens.
* In March 2024, Dexcom secured FDA approval for its updated G7 Continuous Glucose Monitoring system, now offering an extended wear time of approximately 15.5 days, up from the previous 10 days. The device provides real-time glucose readings every five minutes through the Dexcom G7 app and features a 12-hour grace period, allowing users added flexibility when replacing sensors.
* In January 2024, Medtronic plc announced that its MiniMed™ 780G system, now integrated with Simplera Sync, received CE Mark approval.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Continuous Glucose Monitoring devices market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be A close-up of hands holding a tablet and a pen

Description automatically generatedused to assess the competitive landscape in the U.S. Continuous Glucose Monitoring devices market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY COMPONENT**

5.1 Overview

5.2 Sensors

A close-up of hands holding a tablet and a pen

Description automatically generated5.3 Transmitters & Receivers

5.4 Integrated Insulin Pumps

**6 U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY TECHNOLOGY**

6.1 Overview

6.2 Real-time CGM

6.3 Intermittently Scanned CGM

**7 U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY APPLICATION**

7.1 Overview

7.2 Type 1 Diabetes

7.3 Type 2 Diabetes

**8 U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY DEMOGRAPHICS**

8.1 Overview

8.2 Adult

8.3 Paediatrics

**9 U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY CONNECTIVITY**

9.1 Overview

9.2 Bluetooth

* 1. 4G

**10 U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET, BY END USER**

10.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated 10.2 Hospitals & Clinics

10.3 Homecare Settings

10.4 Diagnostic Centers

11 **U.S. CONTINUOUS GLUCOSE MONITORING DEVICES MARKET COMPETITIVE LANDSCAPE**

* 1. Overview
  2. Company Market Ranking
  3. Key Developments Strategies

1. **COMPANY PROFILES**

**12.1 Abbott**

* + 1. A close-up of hands holding a tablet and a pen

       Description automatically generatedOverview
    2. Financial Performance
    3. Product Outlook
    4. Key developments
  1. **Medtronic**

12.2.1 Overview

* + 1. Financial Performance
    2. Product Outlook
    3. Key developments
  1. **Dexcom, Inc**
     1. Overview
     2. Financial Performance

12.3.3Product Outlook

A close-up of hands holding a tablet and a pen

Description automatically generated 12.3.4 Key developments

* 1. **Senseonics Holdings, Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Insulet Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Roche Diabetes Care**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Signos, Inc**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **A. Menarini Diagnostics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. A close-up of hands holding a tablet and a pen

        Description automatically generatedKey developments

* 1. **Johnson & Johnson**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Glysens Incorportaed**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Tandem Diabetes Care**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Nemaura Medical Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Mergers and Acquisitions
   3. A close-up of hands holding a tablet and a pen

      Description automatically generatedBusiness Expansions
   4. Partnerships and Collaborations
2. **Appendix**

14.1 Related Research